MAIA Biotechnology (NYSEAMERICAN:MAIA – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.21, Zacks reports.
MAIA Biotechnology Trading Down 10.9 %
Shares of NYSEAMERICAN:MAIA opened at $2.13 on Friday. MAIA Biotechnology has a one year low of $0.82 and a one year high of $5.99.
Insider Buying and Selling
In other news, Director Cristian Luput bought 22,133 shares of the company’s stock in a transaction dated Friday, November 1st. The stock was bought at an average cost of $2.51 per share, for a total transaction of $55,553.83. Following the completion of the acquisition, the director now owns 389,483 shares in the company, valued at approximately $977,602.33. This trade represents a 6.03 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 36.98% of the stock is owned by company insiders.
About MAIA Biotechnology
MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.
Featured Articles
- Five stocks we like better than MAIA Biotechnology
- How to Calculate Return on Investment (ROI)
- 3 High-Yields Unfazed by the Election: Altria, Truist, Verizon
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Q3 Earnings Indicate On Holdings May Outperform Lululemon in 2024
- 5 discounted opportunities for dividend growth investors
- Cisco Systems Long-Term AI Play Turns a Corner: New Highs Likely
Receive News & Ratings for MAIA Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAIA Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
